Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 24 HOUR vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Relief of nasal congestion associated with common cold, hay fever, and other upper respiratory allergies,Off-label: Eustachian tube congestion
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
120 mg orally every 24 hours (extended-release tablet).
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life 9-16 hours (mean 11 hours) in adults; prolonged in renal impairment (up to 24-30 hours in severe insufficiency); clinically relevant for dosing interval (every 24 hours)
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Primarily hepatic via N-demethylation to active metabolite (norpseudoephedrine); also undergoes oxidative metabolism. CYP450 enzymes involved include CYP2D6.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Renal 70-90% unchanged; minor hepatic metabolism to inactive metabolites; biliary/fecal excretion negligible (<5%)
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Low, approximately 20-30%; primarily binds to albumin
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
2.6-3.5 L/kg; suggests extensive tissue distribution (highly lipophilic)
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 100% (well absorbed); extended-release formulation designed for once-daily dosing
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
GFR 30-50 m L/min: 120 mg every 24 hours; GFR <30 m L/min: not recommended.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
No adjustment necessary; monitor for adverse effects in Child-Pugh C.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 6-11 years: 60 mg orally every 24 hours (extended-release tablet).
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Start with 60 mg orally every 24 hours; increase gradually based on response and tolerability.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None.
None.
May cause hypertension, palpitations, tachycardia, arrhythmias, and stroke; use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or prostatic hypertrophy; avoid in patients with severe hypertension or coronary artery disease; risk of drug dependence with long-term use; avoid use with MAOIs or within 14 days of MAOI therapy.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe hypertension, coronary artery disease, narrow-angle glaucoma, urinary retention, concurrent MAOI therapy or within 14 days, hypersensitivity to pseudoephedrine.
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, soy products) if taking MAOIs. Caffeine may increase stimulant effects. Alcohol may exacerbate CNS side effects.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause fetal tachycardia or arrhythmias. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Pseudoephedrine is excreted in breast milk (M/P ratio ~3.3). May reduce milk production. Use with caution; monitor infant for irritability and sleep disturbances.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustment recommended. However, decreased gastrointestinal motility and increased plasma volume in pregnancy may alter absorption and distribution; use lowest effective dose for shortest duration.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Contains pseudoephedrine HCl 240 mg extended-release. Contraindicated in severe hypertension, coronary artery disease, and MAOI use. Avoid alcohol; may cause insomnia, anxiety, or tachycardia. Advise against bedtime dosing.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Do not crush or chew the tablet; swallow whole with water.,Do not take more than one tablet in 24 hours.,Avoid other products containing pseudoephedrine or other decongestants.,Discontinue if you experience palpitations, chest pain, or dizziness.,Consult a doctor before use if you have high blood pressure, heart disease, diabetes, or glaucoma.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 24 HOUR vs ACTIFED, answered by our medical review team.
SUDAFED 24 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 24 HOUR and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 24 HOUR is: 120 mg orally every 24 hours (extended-release tablet).. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 24 HOUR and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 24 HOUR is classified as Category C. First trimester: No evidence of major malformations in human studies. Second and third trimesters: Potential for uterine vasoconstriction and reduced placental perfusion; may cause. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.